MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584989 | Name: Myricetrin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Myricetrin is a flavonoid that has been found in C. menyharthii leaf extracts and has diverse biological activities.

Chemical Structure

Myricetrin
Myricetrin
CAS#17912-87-7

Theoretical Analysis

MedKoo Cat#: 584989

Name: Myricetrin

CAS#: 17912-87-7

Chemical Formula: C21H20O12

Exact Mass: 464.0955

Molecular Weight: 464.38

Elemental Analysis: C, 54.32; H, 4.34; O, 41.34

Price and Availability

Size Price Availability Quantity
10mg USD 230.00
25mg USD 390.00
50mg USD 635.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Myricetrin; Myricitrine; Myricitroside
IUPAC/Chemical Name
3-[(6-deoxy-α-L-mannopyranosyl)oxy]-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one
InChi Key
DCYOADKBABEMIQ-OWMUPTOHSA-N
InChi Code
InChI=1S/C21H20O12/c1-6-14(26)17(29)18(30)21(31-6)33-20-16(28)13-9(23)4-8(22)5-12(13)32-19(20)7-2-10(24)15(27)11(25)3-7/h2-6,14,17-18,21-27,29-30H,1H3/t6-,14-,17+,18+,21-/m0/s1
SMILES Code
O=C1C(O[C@H]2[C@@H]([C@@H]([C@H]([C@H](C)O2)O)O)O)=C(C3=CC(O)=C(O)C(O)=C3)OC4=CC(O)=CC(O)=C14
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Myricitrin is a major antioxidant flavonoid.
In vitro activity:
Myr (myricitrin) treatment inhibited the lamellipodia formation, migration, and invasion, but not the apoptosis and proliferation, of RA FLSs. Myr also reduced the expression of CCL2, IL-6, IL-8, MMP-1, MMP-3, and MMP-13 induced by TNF-α. The RNA-seq results indicated that AIM2 may be a target gene of Myr in RA FLSs. Reference: Front Pharmacol. 2022 Aug 31;13:905376. https://pubmed.ncbi.nlm.nih.gov/36120327/
In vivo activity:
Myricitrin given by i.p. or p.o. routes produced dose-related antinociception when assessed on acetic acid-induced visceral pain in mice. In addition, the i.p. administration of myricitrin exhibited significant inhibition of the neurogenic pain induced by intraplantar (i.pl.) injection of capsaicin. Like-wise, myricitrin given by i.p. route reduced the nociception produced by i.pl. injection of glutamate and phorbol myristate acetate (PMA). Reference: J Pharmacol Exp Ther. 2006 Feb;316(2):789-96. https://pubmed.ncbi.nlm.nih.gov/16260583/
Solvent mg/mL mM
Solubility
DMSO 65.0 139.97
DMSO:PBS (pH 7.2) (1:5) 0.2 0.34
Ethanol 1.0 2.15
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 464.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Shen C, Xu M, Xu S, Zhang S, Lin W, Li H, Zeng S, Qiu Q, Liang L, Xiao Y, Xu H. Myricitrin inhibits fibroblast-like synoviocyte-mediated rheumatoid synovial inflammation and joint destruction by targeting AIM2. Front Pharmacol. 2022 Aug 31;13:905376. doi: 10.3389/fphar.2022.905376. PMID: 36120327; PMCID: PMC9471193. 2. de Souza AP, Schardosim RF, Al Kateeb JE, Lehmann M, Grivicich I, Dihl RR. Modulatory effect of myricitrin against chromosome instability and cytostasis induced by bleomycin and oxaliplatin in CHO-K1 cells. Drug Chem Toxicol. 2022 Jun 14:1-10. doi: 10.1080/01480545.2022.2085739. Epub ahead of print. PMID: 35702048. 3. Sun GB, Qin M, Ye JX, Pan RL, Meng XB, Wang M, Luo Y, Li ZY, Wang HW, Sun XB. Inhibitory effects of myricitrin on oxidative stress-induced endothelial damage and early atherosclerosis in ApoE-/- mice. Toxicol Appl Pharmacol. 2013 Aug 15;271(1):114-26. doi: 10.1016/j.taap.2013.04.015. Epub 2013 Apr 29. PMID: 23639522. 4. Meotti FC, Luiz AP, Pizzolatti MG, Kassuya CA, Calixto JB, Santos AR. Analysis of the antinociceptive effect of the flavonoid myricitrin: evidence for a role of the L-arginine-nitric oxide and protein kinase C pathways. J Pharmacol Exp Ther. 2006 Feb;316(2):789-96. doi: 10.1124/jpet.105.092825. Epub 2005 Oct 31. PMID: 16260583.
In vitro protocol:
1. Shen C, Xu M, Xu S, Zhang S, Lin W, Li H, Zeng S, Qiu Q, Liang L, Xiao Y, Xu H. Myricitrin inhibits fibroblast-like synoviocyte-mediated rheumatoid synovial inflammation and joint destruction by targeting AIM2. Front Pharmacol. 2022 Aug 31;13:905376. doi: 10.3389/fphar.2022.905376. PMID: 36120327; PMCID: PMC9471193. 2. de Souza AP, Schardosim RF, Al Kateeb JE, Lehmann M, Grivicich I, Dihl RR. Modulatory effect of myricitrin against chromosome instability and cytostasis induced by bleomycin and oxaliplatin in CHO-K1 cells. Drug Chem Toxicol. 2022 Jun 14:1-10. doi: 10.1080/01480545.2022.2085739. Epub ahead of print. PMID: 35702048.
In vivo protocol:
1. Sun GB, Qin M, Ye JX, Pan RL, Meng XB, Wang M, Luo Y, Li ZY, Wang HW, Sun XB. Inhibitory effects of myricitrin on oxidative stress-induced endothelial damage and early atherosclerosis in ApoE-/- mice. Toxicol Appl Pharmacol. 2013 Aug 15;271(1):114-26. doi: 10.1016/j.taap.2013.04.015. Epub 2013 Apr 29. PMID: 23639522. 2. Meotti FC, Luiz AP, Pizzolatti MG, Kassuya CA, Calixto JB, Santos AR. Analysis of the antinociceptive effect of the flavonoid myricitrin: evidence for a role of the L-arginine-nitric oxide and protein kinase C pathways. J Pharmacol Exp Ther. 2006 Feb;316(2):789-96. doi: 10.1124/jpet.105.092825. Epub 2005 Oct 31. PMID: 16260583.
1. Aderogba, M.A., Ndhlala, A.R., Rengasamy, K.R., et al. Antimicrobial and selected in vitro enzyme inhibitory effects of leaf extracts, flavonols and indole alkaloids isolated from Croton menyharthii Molecules 18(10), 12633-12644 (2013). 2. Shimosaki, S., Tsurunaga, Y., Itamura, H., et al. Anti-allergic effect of the flavonoid myricitrin from Myrica rubra leaf extracts in vitro and in vivo Nat. Prod. Res. 25(4), 374-380 (2011).

View History

AH10-7

AH10-7